BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menis J, Litière S, Tryfonidis K, Golfinopoulos V. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med 2016;4:267. [PMID: 27563654 DOI: 10.21037/atm.2016.06.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Korn EL, Freidlin B. Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect. J Clin Oncol 2018;36:2444-9. [PMID: 29949395 DOI: 10.1200/JCO.2018.77.7144] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Fortpied C, Vinches M. The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. Front Oncol 2019;9:634. [PMID: 31355146 DOI: 10.3389/fonc.2019.00634] [Reference Citation Analysis]
3 Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Transl Lung Cancer Res 2021;10:2988-3000. [PMID: 34295692 DOI: 10.21037/tlcr-20-673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Remon J, Menis J, Levy A, De Ruysscher DKM, Hendriks LEL. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 2021;10:3486-502. [PMID: 34430382 DOI: 10.21037/tlcr-20-1065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ruppert AS, Shoben AB. Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs. Contemp Clin Trials Commun 2018;12:40-50. [PMID: 30225393 DOI: 10.1016/j.conctc.2018.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma 2017;4:59-69. [PMID: 28443252 DOI: 10.2147/JHC.S122507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol 2018;39:644-55. [PMID: 30001871 DOI: 10.1016/j.it.2018.06.001] [Cited by in Crossref: 143] [Cited by in F6Publishing: 133] [Article Influence: 35.8] [Reference Citation Analysis]
8 Dong G, Huang B, Chang Y, Seifu Y, Song J, Hoaglin DC. The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards. Pharmaceutical Statistics 2020;19:168-77. [DOI: 10.1002/pst.1977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]